230 related articles for article (PubMed ID: 34439287)
1. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
2. Neuron-specific enolase has potential value as a biomarker for [
Rosar F; Ribbat K; Ries M; Linxweiler J; Bartholomä M; Maus S; Schreckenberger M; Ezziddin S; Khreish F
EJNMMI Res; 2020 May; 10(1):52. PubMed ID: 32449086
[TBL] [Abstract][Full Text] [Related]
3. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
4. Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
Burgard C; Engler J; Blickle A; Bartholomä M; Maus S; Schaefer-Schuler A; Khreish F; Ezziddin S; Rosar F
Front Med (Lausanne); 2023; 10():1339160. PubMed ID: 38298510
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of Posttreatment
Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
[No Abstract] [Full Text] [Related]
7. Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [
Hartrampf PE; Lapa C; Serfling SE; Buck AK; Seitz AK; Meyer PT; Ruf J; Michalski K
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503080
[TBL] [